FNDC5 and breast neoplasm: To the best of our knowledge, this is the first study to explore serum irisin and omentin-1 levels across the spectrum of breast neoplasms, recruiting patients with benign breast lesions as well as newly diagnosed, treatment-naïve cancer patients and individuals who received neoadjuvant chemotherapy and were scheduled for surgical removal of the residual tumor, comparing their levels to healthy controls.